课题基金 / 基金详情

Photoreceptor apoptosis control in animal models for retinitis pigmentosa by caspase inhibitor

Photoreceptor apoptosis control in animal models for retinitis pigmentosa by caspase inhibitor
Caspase抑制剂控制视网膜色素变性动物模型中的光感受器凋亡
批准号:
12671728
负责人:
TSUBURA Airo
金额:
$1.98万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

TSUBURA Airo的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The effect of a caspase-3 inhibitor on photoreceptor apoptosis was investigated. Sixty mg/kg MNU was given intraperitoneally to 50 day old female Sprague-Dawley rats, and 4000 ng Ac-DEVD-CHO, a caspase-3 inhibitor, was injected intravitreally twice at 0 and 10 hr after MNU. In MNU-treated rats, the TUNEL index 24hr post-MNU was 79.5% in the peripheral and 83.7% in the central retina, while the Ac-DEVD-CHO injection significantly reduced it to 59.7% and 71.8%, respectively. Total retinal thickness 7 days after MNU was 38 μm in the peripheral and 75 μm in the central retina. Ac-DEVD-CHO injection increased these values to 72 and 77 μm, respectively. The retinal damage ratio 7 days after MNU was 98.5 %. Ac-DEVD-CHO injection significantly reduced this value to 54.4%, In C3H mice carrying the rd gene, 2 mg/kg of Ac-DEVD-CHO was injected intraperitoneally every other day from 8 days of age, and retinal damage was compared with that in saline-treated mice at 13 days and 17 days of age. At 13 days of age, total and outer retinal thickness in saline-treated mice was 140.3 μm and 37.5 μm, compared with 160.4 μm and 49.5 μm, respectively, in Ac-DEVD-CHO-treated mice (p<0.01, respectively)> However, at 17 days of age, Ac-DEVD-CHO treatment did not ameliorate retinal degeneration. In Both models, the caspase-3 inhibitor was partially effective in suppressing retinal degeneration through inhibition of the apoptosis of photoreceptor cells.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
Yang J: "Retinal damage induced by cisplatin in neonatal rats and mice"Cuff Eye Res. 20(6). 441-446 (2000)
杨J:“顺铂诱导新生大鼠和小鼠的视网膜损伤”Cuff Eye Res。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoshizawa K: "Caspase-3 inhibitor rescues N-methyl-N-nitrosourea-induced retinal degeneration in Sprague-Dawley rats."Exp Eye Res. 71(6). 629-635 (2000)
Yoshizawa K:“Caspase-3 抑制剂可挽救 Sprague-Dawley 大鼠中 N-甲基-N-亚硝基脲诱导的视网膜变性。”Exp Eye Res。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoshizawa K: "Caspase-3 inhibitor transiently delays inherited retinal degeneration in C3H mice carrying the rd gene"Graefes Arch Glin Exp Ophthalmol. (in press).
Yoshizawa K:“Caspase-3 抑制剂可暂时延迟携带 rd 基因的 C3H 小鼠的遗传性视网膜变性”Graefes Arch Glin Exp Ophamol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yoshizawa K: "Cataractogenesis in neonatal Sprague-Dawley rats by N-methyl-N-nitrosourea."Toxicol Pathol. 28(4). 171-179 (2000)
Yoshizawa K:“N-甲基-N-亚硝基脲导致新生 Sprague-Dawley 大鼠白内障发生。”Toxicol Pathol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
11
    Disease control of MNU-induced animal models for retinitis pigmentosa by arachidonic acid and its molecular mechanisms
    • 批准号:
      24592661
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.41万
    • 财政年份:
      2012
    • 负责人:
      TSUBURA Airo
    • 依托单位:
    Mechanisms of sulforaphane-induced breast cancer cell death via autophagy and its application in cancer treatment
    • 批准号:
      21591683
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2009
    • 负责人:
      TSUBURA Airo
    • 依托单位:
    Role of mammary stroma in suppression of parity-induced mammary carcinogenesis and its molecular bases
    • 批准号:
      19591521
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2007
    • 负责人:
      TSUBURA Airo
    • 依托单位:
    Establishment of breast cancer prevention protocol based on hormone milieu of pregnancy and elucidation of its molecular mechanisms
    • 批准号:
      17591361
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.37万
    • 财政年份:
      2005
    • 负责人:
      TSUBURA Airo
    • 依托单位: